Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-IT trial of PB2452 for urgent reversal of ticagrelor
NL-OMON54454Phase 3Completed
- Sponsor
- SFJ Pharmaceuticals
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bentracimab in Not applicable, sponsored by SFJ Pharmaceuticals. Primary endpoints: Primary reversal endpoint and Primary hemostasis endpoint. Started Aug 2021; status: completed.
02
Drugs
bentracimab
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON54454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54454.